That buyout was double the market cap. So a $2 billion US price for us, which seems to me to be the floor for a reasonable offer to take to investors, would need our market cap to 5x from here, maybe a little less when the US dollar inevitably weakens. That market cap is very doable within the next year.
What's interesting about the Abiomed acquisition is that there is a sweetener for shareholders. In addition to the price they were offered per share, Abiomed shareholders get a non-tradeable contingent value right that will pay them an additional amount up to about 9% of the value they got for their shares if certain commercial and clinical milestones are achieved.
WP interview in CEO magazine, page-24
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |